How do Shp2 mutations that oppositely influence its biochemical activity result in syndromes with overlapping symptoms?
Rent the article at a discountRent now
* Final gross prices may vary according to local VAT.Get Access
Activating and inactivating mutations of SHP-2 are responsible, respectively, for the Noonan (NS) and the LEOPARD (LS) syndromes. Clinically, these developmental disorders overlap greatly, resulting in the apparent paradox of similar diseases caused by mutations that oppositely influence SHP-2 phosphatase activity. While the mechanisms remain unclear, recent functional analysis of SHP-2, along with the identification of other genes involved in NS and in other related syndromes (neurofibromatosis-1, Costello and cardio-facio-cutaneous syndromes), strongly suggest that Ras/MAPK represents the major signaling pathway deregulated by SHP-2 mutants. We discuss the idea that, with the exception of LS mutations that have been shown to exert a dominant negative effect, all disease-causing mutations involved in Ras/MAPK-mediated signaling, including SHP-2, might lead to enhanced MAPK activation. This suggests that a narrow range of MAPK signaling is required for appropriate development. We also discuss the possibility that LS mutations may not simply exhibit dominant negative activity.
- How do Shp2 mutations that oppositely influence its biochemical activity result in syndromes with overlapping symptoms?
Cellular and Molecular Life Sciences
Volume 64, Issue 13 , pp 1585-1590
- Cover Date
- Print ISSN
- Online ISSN
- Additional Links
- Noonan syndrome
- LEOPARD syndrome
- Industry Sectors
- Author Affiliations
- 1. Dept. Lipoprotéines et Médiateurs Lipidiques, INSERM U563, Site Purpan, 31024, Toulouse, France
- 2. INSERM U745, Université Paris 5, 4 avenue de l’Observatoire, 75270, Paris, France